416 related articles for article (PubMed ID: 11172140)
1. Enzyme-replacement therapy in mucopolysaccharidosis I.
Kakkis ED; Muenzer J; Tiller GE; Waber L; Belmont J; Passage M; Izykowski B; Phillips J; Doroshow R; Walot I; Hoft R; Neufeld EF
N Engl J Med; 2001 Jan; 344(3):182-8. PubMed ID: 11172140
[TBL] [Abstract][Full Text] [Related]
2. A follow-up study of MPS I patients treated with laronidase enzyme replacement therapy for 6 years.
Sifuentes M; Doroshow R; Hoft R; Mason G; Walot I; Diament M; Okazaki S; Huff K; Cox GF; Swiedler SJ; Kakkis ED
Mol Genet Metab; 2007 Feb; 90(2):171-80. PubMed ID: 17011223
[TBL] [Abstract][Full Text] [Related]
3. Enzyme replacement therapy for mucopolysaccharidosis I: a randomized, double-blinded, placebo-controlled, multinational study of recombinant human alpha-L-iduronidase (laronidase).
Wraith JE; Clarke LA; Beck M; Kolodny EH; Pastores GM; Muenzer J; Rapoport DM; Berger KI; Swiedler SJ; Kakkis ED; Braakman T; Chadbourne E; Walton-Bowen K; Cox GF
J Pediatr; 2004 May; 144(5):581-8. PubMed ID: 15126990
[TBL] [Abstract][Full Text] [Related]
4. Enzyme replacement therapy in patients who have mucopolysaccharidosis I and are younger than 5 years: results of a multinational study of recombinant human alpha-L-iduronidase (laronidase).
Wraith JE; Beck M; Lane R; van der Ploeg A; Shapiro E; Xue Y; Kakkis ED; Guffon N
Pediatrics; 2007 Jul; 120(1):e37-46. PubMed ID: 17606547
[TBL] [Abstract][Full Text] [Related]
5. Long-term efficacy and safety of laronidase in the treatment of mucopolysaccharidosis I.
Clarke LA; Wraith JE; Beck M; Kolodny EH; Pastores GM; Muenzer J; Rapoport DM; Berger KI; Sidman M; Kakkis ED; Cox GF
Pediatrics; 2009 Jan; 123(1):229-40. PubMed ID: 19117887
[TBL] [Abstract][Full Text] [Related]
6. Enzyme replacement therapy in feline mucopolysaccharidosis I.
Kakkis ED; Schuchman E; He X; Wan Q; Kania S; Wiemelt S; Hasson CW; O'Malley T; Weil MA; Aguirre GA; Brown DE; Haskins ME
Mol Genet Metab; 2001 Mar; 72(3):199-208. PubMed ID: 11243725
[TBL] [Abstract][Full Text] [Related]
7. Intrathecal enzyme replacement therapy reduces lysosomal storage in the brain and meninges of the canine model of MPS I.
Kakkis E; McEntee M; Vogler C; Le S; Levy B; Belichenko P; Mobley W; Dickson P; Hanson S; Passage M
Mol Genet Metab; 2004; 83(1-2):163-74. PubMed ID: 15464431
[TBL] [Abstract][Full Text] [Related]
8. Enzyme replacement therapy in mucopolysaccharidosis I: altered distribution and targeting of alpha-L-iduronidase in immunized rats.
Turner CT; Hopwood JJ; Brooks DA
Mol Genet Metab; 2000 Apr; 69(4):277-85. PubMed ID: 10870845
[TBL] [Abstract][Full Text] [Related]
9. A dose-optimization trial of laronidase (Aldurazyme) in patients with mucopolysaccharidosis I.
Giugliani R; Rojas VM; Martins AM; Valadares ER; Clarke JT; Góes JE; Kakkis ED; Worden MA; Sidman M; Cox GF
Mol Genet Metab; 2009 Jan; 96(1):13-9. PubMed ID: 19038563
[TBL] [Abstract][Full Text] [Related]
10. Prediction of neuropathology in mucopolysaccharidosis I patients.
Fuller M; Brooks DA; Evangelista M; Hein LK; Hopwood JJ; Meikle PJ
Mol Genet Metab; 2005 Jan; 84(1):18-24. PubMed ID: 15639191
[TBL] [Abstract][Full Text] [Related]
11. [Hurler syndrome. Early diagnosis and successful enzyme replacement therapy: a new therapeutic approach. Case report].
Dupont C; El Hachem C; Harchaoui S; Ribault V; Amiour M; Guillot M; Maire I; Froissart R; Guffon-Fouilhoux N
Arch Pediatr; 2008 Jan; 15(1):45-9. PubMed ID: 18162380
[TBL] [Abstract][Full Text] [Related]
12. Neurocognitive and somatic stabilization in pediatric patients with severe Mucopolysaccharidosis Type I after 52 weeks of intravenous brain-penetrating insulin receptor antibody-iduronidase fusion protein (valanafusp alpha): an open label phase 1-2 trial.
Giugliani R; Giugliani L; de Oliveira Poswar F; Donis KC; Corte AD; Schmidt M; Boado RJ; Nestrasil I; Nguyen C; Chen S; Pardridge WM
Orphanet J Rare Dis; 2018 Jul; 13(1):110. PubMed ID: 29976218
[TBL] [Abstract][Full Text] [Related]
13. Long-term and high-dose trials of enzyme replacement therapy in the canine model of mucopolysaccharidosis I.
Kakkis ED; McEntee MF; Schmidtchen A; Neufeld EF; Ward DA; Gompf RE; Kania S; Bedolla C; Chien SL; Shull RM
Biochem Mol Med; 1996 Aug; 58(2):156-67. PubMed ID: 8812735
[TBL] [Abstract][Full Text] [Related]
14. Immune tolerance after long-term enzyme-replacement therapy among patients who have mucopolysaccharidosis I.
Kakavanos R; Turner CT; Hopwood JJ; Kakkis ED; Brooks DA
Lancet; 2003 May; 361(9369):1608-13. PubMed ID: 12747881
[TBL] [Abstract][Full Text] [Related]
15. Alpha-L-iduronidase (laronidase; aldurazyme).
Med Lett Drugs Ther; 2003 Oct; 45(1168):88. PubMed ID: 14576624
[No Abstract] [Full Text] [Related]
16. Direct comparison of measures of endurance, mobility, and joint function during enzyme-replacement therapy of mucopolysaccharidosis VI (Maroteaux-Lamy syndrome): results after 48 weeks in a phase 2 open-label clinical study of recombinant human N-acetylgalactosamine 4-sulfatase.
Harmatz P; Ketteridge D; Giugliani R; Guffon N; Teles EL; Miranda MC; Yu ZF; Swiedler SJ; Hopwood JJ;
Pediatrics; 2005 Jun; 115(6):e681-9. PubMed ID: 15930196
[TBL] [Abstract][Full Text] [Related]
17. Identification and molecular characterization of alpha-L-iduronidase mutations present in mucopolysaccharidosis type I patients undergoing enzyme replacement therapy.
Yogalingam G; Guo XH; Muller VJ; Brooks DA; Clements PR; Kakkis ED; Hopwood JJ
Hum Mutat; 2004 Sep; 24(3):199-207. PubMed ID: 15300847
[TBL] [Abstract][Full Text] [Related]
18. Cardiac findings after enzyme replacement therapy for mucopolysaccharidosis type I.
Braunlin EA; Berry JM; Whitley CB
Am J Cardiol; 2006 Aug; 98(3):416-8. PubMed ID: 16860035
[TBL] [Abstract][Full Text] [Related]
19. Immune tolerance improves the efficacy of enzyme replacement therapy in canine mucopolysaccharidosis I.
Dickson P; Peinovich M; McEntee M; Lester T; Le S; Krieger A; Manuel H; Jabagat C; Passage M; Kakkis ED
J Clin Invest; 2008 Aug; 118(8):2868-76. PubMed ID: 18654665
[TBL] [Abstract][Full Text] [Related]
20. Enzyme replacement therapy with laronidase (Aldurazyme(®)) for treating mucopolysaccharidosis type I.
Jameson E; Jones S; Remmington T
Cochrane Database Syst Rev; 2016 Apr; 4():CD009354. PubMed ID: 27033167
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
